we discuss the changing landscape of the management of patients with metastatic hormonesensitive prostate cancer in the context of several recently-published landmark randomized trials.In addition,we discuss several unresolved issues,including the optimal sequencing of systemic treatments and the ...
have some adverse effects, to maintain its quality-of-life metrics compared with placebo over the long haul while having a very acceptable safety profile, this demonstrates that we need to heavily consider the use of combination therapy with our men with metastatic hormone-sensitive prostate cancer...
Alicia Morgans, M.D., MPH: Metastatic hormone-sensitive prostate cancer is a particular type or stage of prostate cancer in which the cancer has spread outside of the prostate—that's the metastatic term—and hormone-sensitive means that it hasn't yet been treated with androgen deprivation the...
Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Ther...
Concurrently, the incidence of metastatic hormone-sensitive prostate cancer (mHSPC) at diagnosis has significantly risen as a result, in part, of recent advances in imaging. Given the increased utilization of prostate-specific membrane antigen鈥搕argeted positron emission tomography imaging and other ...
We wish to express our concern and disagreement with the (grade 1A) recommendation in the ESMO clinical practice guidelines for prostate cancer [1] that: ‘androgen deprivation therapy (ADT) plus docetaxel is recommended as first-line treatment of metastatic, hormone-naïve disease in men fit en...
EP: 5.Clinical Perspectives from the ARANOTE Trial in Metastatic Hormone-Sensitive Prostate Cancer EP: 6.Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC EP: 7.Insights From ARANOTE and Clinical Practice EP: 8.The Evolving Role of Radium-223 in mCRPC and the Imp...
Here we review the evidence surrounding the use of radiation therapy to metastatic sites in patients with metastatic hormone-sensitive prostate cancer.doi:10.1097/PPO.0000000000000429Deek, Matthew P.Phillips, RyanTran, Phuoc T.The Cancer Journal
Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): a correlative study of E3805 CHAARTED. Presented at: ASCO Annual Meeting; 2019; Chicago, IL. 14. Cerami E, Gao J, Dogrusoz U, et al. The ...
ADT intensification is now a standard of care in the management of metastatic prostate cancer. This intensification is discussed in relation to the patient and the characteristics of the disease. For all metastatic hormone-sensitive PC (synchronous and metachronous), the overall survival benefit ...